glp-1 and type 2 diabetes Novel GLP-1–Based Medications for Obesity GLP-1 receptor agonists in the

The SURMOUNT-1 trial formally assessed weight loss of tirzepatide against placebo in obesity

P., Stenvers, D

Three to four sessions per week focusing on compound movements, squats, deadlifts, bench press, rows, and overhead press, provides the mechanical stimulus your muscles need to maintain mass during caloric deficit

Alternative medications or formulations may be discussed with prescribers

The average change in body weight was 2.6kg (with the 0.75mg weekly dose of Trulicity) and 3kg (with the 1.5mg weekly dose of Trulicity)

Incidence rates for RA, gout, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, psoriatic arthritis, and osteoarthritis within 1 year after the index date served as the primary outcome